Aarti Drugs Ltd

Aarti Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Drugs Ltd

₹ 491 1.11%
17 May - close price
aartidrugs.com BSE: 524348 NSE: AARTIDRUGS
About

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]

It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

Key Points

Largest producer in World
Aarti Drugs Ltd. (ADL) is the largest producer of Fluoroquinolones group, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole in the world. It is one of the leading producers of Metformin in the world. [1]

Website BSE NSE
  • Market Cap ₹ 4,503 Cr.
  • Current Price ₹ 491
  • High / Low ₹ 646 / 430
  • Stock P/E 31.7
  • Book Value ₹ 128
  • Dividend Yield 0.20 %
  • ROCE 13.5 %
  • ROE 12.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 9.28% over past five years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 5.76% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -3.07%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
452 506 511 593 641 551 625 626 696 592 578 538 560
374 432 442 503 557 496 555 557 608 520 512 478 490
Operating Profit 78 74 69 91 84 55 70 69 89 72 65 60 69
OPM % 17% 15% 14% 15% 13% 10% 11% 11% 13% 12% 11% 11% 12%
1 2 1 2 1 0 0 1 1 1 1 2 1
Interest 4 4 5 5 6 7 8 9 8 8 8 7 8
Depreciation 12 12 12 12 12 12 12 12 12 12 12 12 12
Profit before tax 63 60 53 75 67 36 50 49 69 53 47 43 50
Tax % 21% 24% 24% 26% 21% 28% 27% 25% 23% 25% 26% 26% 27%
50 46 41 56 53 26 37 37 53 40 35 32 36
EPS in Rs 5.39 4.92 4.39 6.03 5.72 2.85 3.95 3.96 5.74 4.27 3.76 3.44 3.93
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
826 972 1,087 1,076 1,089 1,140 1,454 1,635 1,915 2,251 2,498 2,267
703 822 915 900 910 955 1,252 1,387 1,511 1,930 2,212 2,001
Operating Profit 123 150 172 176 179 185 203 248 404 321 286 266
OPM % 15% 15% 16% 16% 16% 16% 14% 15% 21% 14% 11% 12%
-0 1 1 0 4 1 6 9 7 5 2 4
Interest 31 37 42 47 38 36 41 36 26 23 36 30
Depreciation 26 28 31 36 37 38 40 47 48 47 47 48
Profit before tax 66 86 100 93 108 112 128 175 338 256 205 192
Tax % 31% 28% 22% 29% 30% 35% 32% 22% 24% 24% 25% 26%
45 62 78 66 75 73 87 136 258 195 153 142
EPS in Rs 4.67 6.38 8.01 6.84 7.91 7.78 9.25 14.56 27.65 21.06 16.50 15.43
Dividend Payout % 27% 26% 41% 25% 3% 3% 3% 3% 9% 5% 6% 6%
Compounded Sales Growth
10 Years: 9%
5 Years: 9%
3 Years: 6%
TTM: -9%
Compounded Profit Growth
10 Years: 9%
5 Years: 11%
3 Years: -18%
TTM: -7%
Stock Price CAGR
10 Years: 26%
5 Years: 28%
3 Years: -14%
1 Year: 5%
Return on Equity
10 Years: 20%
5 Years: 20%
3 Years: 16%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 12 12 24 24 24 24 24 23 93 93 93 92
Reserves 196 239 279 326 363 410 495 598 766 880 1,022 1,083
296 342 435 465 448 517 471 378 336 519 535 475
216 257 228 240 281 366 384 471 442 543 546 522
Total Liabilities 720 850 967 1,055 1,116 1,316 1,373 1,471 1,637 2,035 2,195 2,172
291 373 431 463 542 564 586 612 631 649 634 722
CWIP 13 8 13 34 14 28 32 11 16 60 161 222
Investments 5 5 11 11 18 17 19 20 24 28 29 30
411 464 511 547 541 707 736 828 966 1,297 1,372 1,198
Total Assets 720 850 967 1,055 1,116 1,316 1,373 1,471 1,637 2,035 2,195 2,172

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
72 95 107 125 174 62 147 196 154 40 162 337
-58 -105 -102 -87 -96 -71 -59 -29 -69 -125 -131 -187
-16 11 -5 -37 -78 9 -87 -168 -85 84 -31 -149
Net Cash Flow -2 2 -1 1 -0 -0 1 -1 -0 -1 1 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 95 104 103 109 93 117 110 104 96 115 117 104
Inventory Days 95 71 77 87 101 132 86 107 125 120 102 105
Days Payable 88 84 75 85 91 125 86 110 94 103 89 94
Cash Conversion Cycle 101 91 105 110 103 124 109 101 127 133 130 115
Working Capital Days 101 90 97 108 103 128 108 95 118 132 130 117
ROCE % 20% 22% 21% 18% 17% 17% 17% 20% 33% 21% 15%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
60.14% 60.12% 59.99% 59.83% 59.98% 59.77% 59.66% 59.57% 58.70% 58.57% 57.47% 57.13%
2.57% 2.21% 2.03% 2.07% 2.07% 1.94% 1.90% 1.94% 1.97% 2.33% 2.10% 2.56%
2.00% 2.12% 2.28% 2.69% 2.76% 3.16% 3.90% 4.09% 4.72% 5.32% 5.26% 5.99%
35.29% 35.55% 35.71% 35.41% 35.19% 35.11% 34.53% 34.39% 34.63% 33.78% 35.16% 34.30%
No. of Shareholders 1,77,9931,83,3441,95,4691,89,6071,86,6741,80,3031,73,2831,69,0901,62,4091,67,4461,70,4141,57,547

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls